150 related articles for article (PubMed ID: 37023368)
21. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.
Oliveira ML; Akkapeddi P; Ribeiro D; Melão A; Barata JT
Adv Biol Regul; 2019 Jan; 71():88-96. PubMed ID: 30249539
[TBL] [Abstract][Full Text] [Related]
22. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
[TBL] [Abstract][Full Text] [Related]
23. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG; Buijs-Gladdines JGCAM; Cordo' V; Debets DO; Smits WK; Chen Z; Dylus J; Zaman GJR; Altelaar M; Oshima K; Bornhauser B; Bourquin JP; Cools J; Ferrando AA; Vormoor J; Pieters R; Vormoor B; Meijerink JPP
Leukemia; 2021 Dec; 35(12):3394-3405. PubMed ID: 34007050
[TBL] [Abstract][Full Text] [Related]
24. IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers.
Sasson SC; Smith S; Seddiki N; Zaunders JJ; Bryant A; Koelsch KK; Weatherall C; Munier ML; McGinley C; Yeung J; Mulligan SP; Moore J; Cooper DA; Milliken S; Kelleher AD
Cytokine; 2010 Apr; 50(1):58-68. PubMed ID: 20060740
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
26. CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
Walker KL; Rinella SP; Hess NJ; Turicek DP; Kabakov SA; Zhu F; Bouchlaka MN; Olson SL; Cho MM; Quamine AE; Feils AS; Gavcovich TB; Rui L; Capitini CM
Leuk Lymphoma; 2021 May; 62(5):1167-1177. PubMed ID: 33843403
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2 priming chemotherapy: a strategy to improve the remission of refractory/relapsed T cell acute lymphoblastic leukemia.
Zhang C; Zhang X; Chen XH
Med Hypotheses; 2013 Nov; 81(5):878-80. PubMed ID: 24074835
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.
Senkevitch E; Li W; Hixon JA; Andrews C; Cramer SD; Pauly GT; Back T; Czarra K; Durum SK
Oncotarget; 2018 Apr; 9(32):22605-22617. PubMed ID: 29854301
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
Treanor LM; Zhou S; Janke L; Churchman ML; Ma Z; Lu T; Chen SC; Mullighan CG; Sorrentino BP
J Exp Med; 2014 Apr; 211(4):701-13. PubMed ID: 24687960
[TBL] [Abstract][Full Text] [Related]
30. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
Zhang J; Ding L; Holmfeldt L; Wu G; Heatley SL; Payne-Turner D; Easton J; Chen X; Wang J; Rusch M; Lu C; Chen SC; Wei L; Collins-Underwood JR; Ma J; Roberts KG; Pounds SB; Ulyanov A; Becksfort J; Gupta P; Huether R; Kriwacki RW; Parker M; McGoldrick DJ; Zhao D; Alford D; Espy S; Bobba KC; Song G; Pei D; Cheng C; Roberts S; Barbato MI; Campana D; Coustan-Smith E; Shurtleff SA; Raimondi SC; Kleppe M; Cools J; Shimano KA; Hermiston ML; Doulatov S; Eppert K; Laurenti E; Notta F; Dick JE; Basso G; Hunger SP; Loh ML; Devidas M; Wood B; Winter S; Dunsmore KP; Fulton RS; Fulton LL; Hong X; Harris CC; Dooling DJ; Ochoa K; Johnson KJ; Obenauer JC; Evans WE; Pui CH; Naeve CW; Ley TJ; Mardis ER; Wilson RK; Downing JR; Mullighan CG
Nature; 2012 Jan; 481(7380):157-63. PubMed ID: 22237106
[TBL] [Abstract][Full Text] [Related]
31. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
32. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutation of IL7R exon 6 in acute leukemias and solid cancers.
Kim MS; Chung NG; Kim MS; Yoo NJ; Lee SH
Hum Pathol; 2013 Apr; 44(4):551-5. PubMed ID: 23069254
[TBL] [Abstract][Full Text] [Related]
34. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
[TBL] [Abstract][Full Text] [Related]
35. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
36. Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.
Cleaver AL; Beesley AH; Firth MJ; Sturges NC; O'Leary RA; Hunger SP; Baker DL; Kees UR
Mol Cancer; 2010 May; 9():105. PubMed ID: 20459861
[TBL] [Abstract][Full Text] [Related]
37. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Lato MW; Przysucha A; Grosman S; Zawitkowska J; Lejman M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925883
[TBL] [Abstract][Full Text] [Related]
38. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-NTRK3 fusion.
Zhou K; Gong D; He C; Xiao M; Zhang M; Huang W
Mol Carcinog; 2023 Jul; 62(7):899-906. PubMed ID: 37036164
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
Meyer LK; Delgado-Martin C; Sharp PP; Huang BJ; McMinn D; Vincent TL; Ryan T; Horton TM; Wood BL; Teachey DT; Taunton J; Kirk CJ; Hermiston ML
Br J Haematol; 2022 Jul; 198(1):137-141. PubMed ID: 35434798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
